Mice were exposed for 8 h to continuous small-particle aerosols containing natural mouse alpha interferon (estimated dosage 100 U per mouse) or one of two concentrations of hybrid recombinant alpha interferon A/D bgl (estimated dosages of 100 and 10,000 U per mouse, respectively). On days 1, 3, 5, 7, and 9 after exposure to these interferons, three mice from each group were inoculated intranasally with 100 PFU of vesicular stomatitis virus. Control mice were exposed to aerosols of saline or inoculated intraperitoneally with either natural mouse alpha interferon (350 U) or one of two doses of hybrid recombinant alpha interferon A/D bgl (350 or 35,000 U) and challenged similarly. Of mice injected intraperitoneally, only those given 35,000 U of hybrid recombinant alpha interferon A/D bgl 24 h before virus challenge were protected from pulmonary infection, compared with the saline-treated control mice. Of mice given 100 U of either interferon by small-particle aerosol, only those exposed 24 h before inoculation of vesicular stomatitis virus had reduced pulmonary titers of the virus. However, of mice given ca. 10 ,000 U of hybrid recombinant alpha interferon A/D bgl by small-particle aerosol, all groups except those exposed 9 days before virus inoculation had significantly reduced lung virus titers.
Because of their high specific molecular activity and broad spectrum of antiviral activity, interferons have a potential role for preventing and treating many human respiratory viral infections (2, 11) . Numerous trials that involve the use of interferon inducers or preparations of interferons administered locally or parenterally to treat experimentally induced respiratory virus infections have been carried out (2-6, 10, 15, 16, 20) . The results of these trials have varied, but with findings obtained from in vitro tests (8, 9) , they suggest that the efficacy of human leukocyte interferon in preventing respiratory virus infections is dependent both on the time that the respiratory epithelium is exposed to test interferons and on the concentration of the materials used. Administration of interferons by continuous small-particle aerosols (SPAs) may provide a better method of delivering interferons to the respiratory tract than those used previously. We have reported elsewhere that when given by SPA, interferons deposit in the lungs of exposed mice and reach levels comparable to those seen for endogenous interferons induced after natural virus infection (23) . We also observed that exposure of cotton rats (21a) or mice (24) to SPAs of interferons initiated within 24 h of virus challenge could protect these animals from vesicular stomatitis virus (VSV)-induced pulmonary infection. In this report we compare the effectiveness of aerosols of natural mouse alpha interferon (MoIFN) and recombinant human leukocyte interferon alpha A/D bgl (rIFN alpha A/D), an interferon that is uniquely active in both human and mouse tissue cells, in reducing VSV pulmonary infection when given for a single 8-h interval 1 to 9 days before virus inoculation. The results showed that when delivered at sufficient concentrations by SPA, interferon given 1, 3, 5, or 7, but not 9 days before virus challenge, was protective.
MATERIALS AND METHODS
Mice. Male Swiss outbred mice, 6 to 9 weeks old, were * Corresponding author.
obtained from Charles River Breeding Laboratories, Inc., Wilmington, Mass. These mice were housed in cages covered with barrier filters and fed mouse chow and water ad libitum.
Virus. Stocks of VSV were prepared by infecting flasks of mouse fibroblast (L929) cells with seed virus and harvesting the cells and media when more than 90% cytopathic effect (CPE) was observed. After one freeze-thaw cycle, the resulting suspensions were centrifuged (100 x g) to remove cellular debris, portioned, and stored at -70°C. The titer of this pool was 2 x 107 PFU/ml. Virus inoculations. On days 1, 3, 5, 7, or 9 after interferon or saline administration, three mice from each group were lightly anesthetized with ether and inoculated intranasally with 100 PFU (0.05 ml) of VSV. This dose was usually not lethal but produced an asymptomatic disease which was not evident except by isolation of virus from infected lungs or by histopathological changes evident in thin sections of lung stained with hemotoxylin and eosin.
Tissue cultures. L929 cells (no. 03-439) were obtained from Flow Laboratories, McLean, Va.; Madin Darby bovine kidney (MDBK) cells were provided by the Department of Experimental and Applied Biology, Hoffmann-La Roche, Inc., Nutley, N.J. Cultures of both cell lines were routinely passaged when confluent by using Eagle minimal essential medium supplemented with 2 mM L-glutamine, 100 U of penicillin per ml, 100 ,ug of streptomycin per ml, 0.2% sodium bicarbonate, and 10% fetal calf serum.
Interferons. rIFN alpha A/D was obtained from the Department of Experimental and Applied Biology, Hoffman-La Roche, Inc. The construction and specific molecular activity of this interferon has been described previously (17, 18 b Estimated maximum dosage of interferon delivered per mouse = respiratory volume per min for mice (7) x 60 (min/h) x 8 h x the estimated retention value (21a) x concentration of interferon in the interferon delivery reservoir x coefficient of output for the aerosol generator used (14, 22) , e.g., 25 cm3/min x 60 (min/h) x 8 h x 0.5 x (1.7 x 105) U/cm3 x (10-5) = 1.0 X 104 U.
active against VSV in L929 cells and has comparatively little activity in MDBK or WISH cells (18, 24) .
Human type alpha (no. G-023-901-527, National Institute of Allergy and Infectious Diseases, Bethesda, Md.) and mouse type 1 (no. G-002-904-511, National Institute of Allergy and Infectious Diseases) interferon reference reagents were obtained from June K. Dunnick and John R. LaMontagne of the Antiviral Substance Program of the National Institute of Allergy and Infectious Deseases.
Measurement of antiviral activity. Assays were performed in 96-well, round-bottomed plates (no. 76-013-05, Flow Laboratories, McLean, Va.). Each assay was performed in duplicate and in parallel in L929 and MDBK cells. Briefly, 0.05 ml of medium, test sample, or interferon reference standard was added to the first well of a row and serially diluted (twofold) by using microtiter loops (Rotatiter; no. 002-961-0100, Dynatech Laboratories, Inc., Alexandria, Va.) After the addition of the appropriate tissue cells (ca. 2 x 104 cells in 0.05 ml) to each well, the plates were incubated at 37°C overnight in a CO2 (5%) incubator. The next morning, the medium was removed with a suction device, and ca. 100 PFU of VSV (in 0.1 ml) was added to each well. Virus-infected control wells were observed daily. When the CPE was 90 to 100% in these wells (usually at 48 h), the degree of CPE in all wells was recorded. Titers were expressed as units (log2), with 1 U being equal to the dilution which inhibited the CPE by 50% compared with the virus controls. All titers obtained in L929 cells were adjusted according to the stated titer of the National Institutes of Health mouse interferon reference standard; similarly, titers obtained in MDBK cells were calculated relative to the National Institutes of Health human interferon reference standard.
Interferon administration and dosages. Mice were either given single (0.1-ml) injections of MoIFN (350 U per mouse) or rIFN alpha A/D (350 or 35,000 U per mouse) intraperitoneally (i.p.) or exposed to a continuous SPA of one of these materials for 8 h ( Table 1 .) The aerosol generators and their use to deliver interferons (23) or other antiviral agents (12, 13, 22) have been described previously. In these experiments, rIFN alpha A/D was diluted in sterile saline (0.9% sodium chloride no. 0338-0049-02, Travenol Laboratories, Inc., Deerfield, Ill.) to a concentration of 1.7 x 105 or 1.7 x 103 U/ml and placed in delivery reservoirs (500-ml polypropylene beakers; no. 146706, Spectrum Medical Industries). The MoIFN was handled similarly but used only at a concentration of 1.7 x 103 U/ml. Virus control mice were exposed to aerosols containing saline without any interferons. Interferon control mice were exposed to or injected with the interferons but not inoculated with virus. The estimated maximum dosage received by each mouse exposed to MoIFN or the lower concentration of rIFN alpha A/D was 100 U per mouse and by mice exposed to the higher concentration of rIFN alpha A/I, 10,000 U per mouse (see Table 1 Sera from all test mice showed some antiviral activity. In uninoculated animals this activity was generally <4.0 log2 and was most probably due to nonspecific virus inhibitors present in the sera, since unlike natural mouse interferon (18) , the inhibition was active in both MDBK and L929 cells and always present. However, after i. (Table 3 ). The interferon titers in the lungs of groups receiving ca. 100 U of either MoIFN or rIFN alpha A/D per mouse reached significant levels by 1 h, maximal levels at 8 h (at which time the aerosol administrations were stopped), and were back to base-line values 16 h later (24 h after starting the experiment). No significant increases in antiviral activity were observed at any test interval in sera from animals exposed to 100 U of either interferon.
Animals which received 104 U of rIFN alpha A/D by aerosol showed significant antiviral activity in their lungs within 30 min of initiation of aerosol administration, had maximal activity in the 4-to 8-h interval, and did not show a fall in interferon titers until the aerosol admninistrations were stopped (after 8 h). Maximum values of interferon in this group were fourfold greater than in groups exposed to the lower doses of interferons. Low levels of interferon were still present in the lungs of these animals at 24 h but no antiviral activity was detectable in the lungs of this group at 48 h. No significant rises in antiviral activity were observed at any time in the sera from these animals.
Pulmonary virus titers. Pulmonary titers of VSV in each test group of mice are shown in Table 4 . Mice given 35,000 U of rIFN alpha A/D 24 h before virus challenge had reduced pulmonary virus titers when compared with control mice given saline; however, these were the only mice inoculated parenterally which were protected. After aerosol administration of interferons, the group exposed to 100 U of MoIFN and the group exposed to 100 U of rIFN alpha A/D 24 h before challenge had significantly reduced lung virus titers compared with those of the control mice. Mice exposed to 104 U of rIFN alpha A/D and challenged with virus 1, 3, 5, or 7 days after interferon exposure were also protected. No protective effect was seen in mice challenged with virus 9 days after being exposed to rIFN alpha A/D by SPA.
DISCUSSION
These studies have demonstrated the greater effectiveness of interferons given in aerosol over those given i.p. in the suppression of VSV growth in the lungs of mice challenged 1 to 7 days after interferon administration. Moreover, they clearly point out the importance of concentration in determining the efficacy of interferons delivered to the lungs. The highest dose of rIFN alpha A/D when given by SPA abolished virus from the lungs in animals inoculated 24 h after the end of the 8-h aerosol treatment. There was also a significant but diminishing antiviral effect with this dose in nmice challenged at 3, 5, and 7 days; there was no effect at 9 days after this dose of interferon was administered. A lower Limited transport to the lung of parenterally administered interferons may have accounted for the relatively low efficacy observed in these studies for i.p. injected interferons (1, 3, 5, 6, 21) . Assays for interferon independent of the VSV challenges revealed that interferon could be detected after i.p. administration only when the largest dose had been given. In contrast, interferon was detected in the lungs after aerosol administration of both the low doses of the MoIFN and IFN alpha A/D and the high dose of human interferon. These findings indicate the validity of the aerosol administration of interferon in the treatment of pulmonary infections. Some failures of interferon to affect the course of pulmonary virus infections in earlier studies may have resulted from the inadequate delivery of the preparation rather than from intrinsic lack of effectiveness of interferon.
